AUTOIMMUNE DISEASE TREATMENT MARKET ANALYSIS

According to National Institute of Health (NIH), there were approximately 23.5 million American’s suffering from an autoimmune disease in 2012. Moreover, Department of Health and Human Services, in 2017, reported that autoimmune disease (AID) is ranked first in the top ten list of popular health topics. Autoimmune disease has a severe impact on a health, which may lead to various complications in different part of the body, such as heart, brain, kidneys, glands, and nerves. Increasing rate of autoimmune disease is mainly due to genetic and environmental factors, which include dietary components, toxic chemical, and infections. Autoimmune diseases include inflammatory bowel diseases (IBD), rheumatic arthritis (RA), multiple sclerosis (MS), celiac disease (CD), hepatitis, autoimmune thyroiditis (AT), systemic lupus erythematous (SLE) and type 1 diabetes (IDDM).  According to International Journal of Celiac Disease, in 2015, stated that the environmental factors are strongly related to cause autoimmune diseases, which include infections, ecology, and nutrition.

Diagnosis of AID is challenging due to lack of basic knowledge about disease pattern, to identify treatments, and design clinical trials. Increasing awareness among the population about autoimmune diseases and its complications is expected to contribute towards the growth of autoimmune disease treatment market. 

Global Autoimmune Disease Treatment Market Taxonomy –

By Disease Types –

• Systemic
• Organ-specific

By Drug Type –

• Immunosuppressant’s
• Anti-Inflammatory Drugs
• Corticosteroids
• Nonsteroidal anti-inflammatory drugs
• Others

Advanced approaches for the treatment of AID is expected favor the growth of autoimmune disease treatment market

Innovation in the treatment of AID is expected to augment the autoimmune disease treatment market. For instance, researchers at the Perelman School of Medicine in 2016, found a way to target a specific subset of antibody, which is responsible for the activation of pemphigus vulgaris (PV) autoimmune disease. The researchers designed chimeric autoantibody receptor therapy (CAART) that can be used to treat this disease without harming the healthy immune system.

Moreover, researchers at the Cumming School of Medicine in 2016, developed a new class of Nano-medicine to treat diseases, specifically type 1 diabetes, multiple sclerosis, and rheumatoid arthritis without compromising immunity. This Nano-medicine is currently being developed at Parvus Therapeutics, Inc., and is funded by Innovate Calgary.

Advancements in research are providing new options for treatment of autoimmune diseases. For instance, StemGenex Medical group registered with National Institute of Health (NIH) in June 2017, to provide stem cell therapy for five different diseases, which include multiple sclerosis, Parkinson’s disease, Rheumatoid arthritis, chronic obstructive pulmonary disease, and osteoarthritis. Moreover, the American Autoimmune Related Diseases Association, Inc. (AARDA) in 2016 conducted a study on potential cause of AID and its treatment by using genetic element (reteroelements) as LINE-1. However, the findings of the studies are not confirmed yet.

According to the American Autoimmune Related Diseases Association (AARDA), in 2017, approximately 50 million Americans are suffering from autoimmune disease. High prevalence of autoimmune diseases demands for new treatment approach, which may include biomarkers, stem cell research, and genetic research. Biological agents such as TNF agents, monoclonal antibodies, tissue and organ engineering procedure, gene-based delivery system, modulators of the immune system, and cell-based treatments are under evaluation for the treatment of AID in near future.

Rising awareness regarding autoimmune diseases and increasing demand for the therapeutic approaches is expected to favor the growth of autoimmune disease treatment market

Government and biopharmaceutical are investing in research and development activities to develop novel drugs and therapies for autoimmune disease treatment, which is expected to be the major driving factor for the growth of autoimmune disease treatment market in near future.

According to the Centers for Disease Control and Prevention (CDC), the prevalence of arthritis from 2013 to 2015, was estimated at 54.4 million in the U.S. adults (22.7%) and by 2040, it is expected to be 78 million (26%). As per CDC, prevalence has been increasing more rapidly in middle-low income economies, which is the major factors fueling the growth of autoimmune disease treatment market. According to a case report by BioMed Central, 2015, increasing chronic infections and disorder, for instance, SLE associated with pregnancy can lead to maternal, obstetric, and fetal problems, in turn fueling the growth of autoimmune disease treatment market in near future. High-cost therapy options are the major restraint for AID treatment market, which has negative impact on therapeutics market.

Key players operating the global autoimmune disease treatment market include Johnson & Johnson, Abbott Laboratories, F. Hoffmann-La Roche Ltd., Active Biotech, GlaxoSmithKline plc, Eli Lilly and Company, AutoImmune Inc., Pfizer, Inc. AstraZeneca plc, Lupin Limited, 4SC AG, Amgen, Inc., and Bristol-Myers Squibb.